AMRX - FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203

• The US FDA has accepted Amneal Pharmaceuticals' ( NYSE: AMRX ) NDA for IPX203 (carbidopa/levodopa) for Parkinson's disease.
• The agency has provided an action date of June 30, 2023.
• IPX203 is novel, oral formulation of extended-release carbidopa/levodopa.
• Phase 3 data showed that IPX203 led to significantly more "good on" time, as well as significantly less "off" time, compared to the immediate-release version, even when dosed less often.
• See why Seeking Alpha contributor Bret Jensen rates Amneal ( AMRX ) a hold.

For further details see: